220 results about "Tilmicosin" patented technology

The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C₈-C₂₂ fatty acid, and preferably may be a saturated or unsaturated C₁₀-C₁₈ fatty acid. The compounds precipitate in aqueous environments. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a period of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.

The invention discloses a preparation method of tilmicosin. The method comprises the following steps of: reacting tylosin phosphate serving as a raw material with 3,5-lupetidine by taking alcohol as a solvent and taking anhydrous formic acid as a catalyst at 65-97 DEG C to obtain 20-dihydro-20-deoxy-(3,5-lupetidine-1-radical)tylosin serving as an intermediate; concentrating the solvent; and adding residues into 0.1N sulfuric acid solution for hydrolyzing to obtain tilmicosin, wherein the mass volume ratio of the tylosin phosphate to the alcohol is 1:(2-10), the mass ratio of the tylosin phosphate to the 3,5-lupetidine to the anhydrous formic acid is 1:(0.11-0.17):(5.6-8), and the mass volume ratio of the tylosin phosphate to the 0.1N sulfuric acid solution is 1:(2-6). The reaction formula is shown in the specifications. By adopting the method, the defects of the prior art can be overcome. The method is easy to control, and has high yield and low production cost.

The invention discloses a tilmicosin solid dispersible granule as well as a preparation method and an application thereof. The tilmicosin solid dispersible granule consists of tilmicosin and a carrier accessory. The carrier accessory is one of glycerin monostearate, stearyl alcohol, saturated triglyceride, glycerinum simple lipid, paraffin wax, animal wax, vegetable wax or fatty powder or mixture thereof. The preparation method of the tilicosin solid dispersible granule comprises the following steps: weighing respective carrier accessories according to the formula proportion, heating, melting and mixing uniformly; adding the tilmicosin, stirring uniformly, cooling, pelleting through spraying of a fluidized bed, balling, cooling, sieving and collecting to obtain the tilmicosin solid dispersible granule. The tilmicosin solid dispersible granule solves the problem of medicine palatability, by feed mixing administration, the fluidity and dispersibility are good and medication is convenient; after animals take the granule, the medicine releases slowly, so that the safety is high; besides, the biological availability of tilmicosin medicine is enhanced, and the clinical using effect is remarkable.

The invention relates to an enteric-coated tilmicosin slow-release micro-capsule preparation and a preparation method thereof and belongs to the field of tilmicosin preparations. The enteric-coated tilmicosin slow-release micro-capsule preparation provided by the invention comprises an inner core layer and a coating layer, wherein the inner core layer comprises tilmicosin raw powder and an auxiliary material; the auxiliary material comprises one or more than one of stearic acid, glycerin monostearate, stearyl alcohol, saturated triglyceride, monoglyceride and paraffin; and the coating layer is made from one or more than one of cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, acrylic resin, polyvinyl acetate phthalate and acetic hydroxypropyl methylcellulose succinate. The preparation method comprises the following steps of: carrying out primary coating on the tilmicosin raw powder and the auxiliary material, carrying out secondary coating by using the materials of the coating layer, and drying to obtain the finished product. According to the invention, the tilmicosin is coated by using high polymer materials and the coated tilmicosin micro-capsule is undissolved in acid environment and slowly dissolved in alkaline environment of enteric canal, so that the purpose of slow release is achieved and the action time of the tilmicosin is prolonged.

The present invention provides a tilmicosin dry suspension. The invention also provides a method for preparing the dry suspension and uses thereof. According to the tilmicosin dry suspension of the present invention, via reasonable compatibility of excipients, dispersion of tilmicosin in water is significantly improved, so the tilmicosin is enabled to be evenly distributed in the water in a long time, convenient for clinical administration of medicine by drinking water. Meanwhile, the dry suspension has greatly improved the palatability of the tilmicosin, so the dry suspension can be used not only for animal groups with underdeveloped taste such as chickens, but also for other animal groups with sensitive taste such as pigs, thus expanding the scope of application of the product.

The invention belongs to the veterinary medicine residual analysis and immunity analysis technique field and specifically relates to an enzyme-linked immunity method and the reagent kit thereof which can discern specificity monoclonal antibodies of tylosin and tilmicosin and detect the residuals of tylosin and tilmicosin at the same time; the monoclonal antibodies in the invention is secreted from hybridoma cell strain P3C4 established by the applicant; the hybridoma cell strain is preserved in China Center of Type Culture Collection; the number of preservation of the hybridoma cell strain is CCTCC No: C200719; the invention discloses the preparation method and enzyme-linked immunity detection method of the monoclonal antibody, coating antigen and immunogen. Compared with the prior art, the monoclonal antibody prepared in the invention can discern tylosin and tilmicosin at the same time and add the detecting object in the prior art. The reagent kit and the method in the invention has the advantages of simple, convenience, swiftness, sensitivity and accuracy; furthermore, the reagent kit and method in the invention can detect the residuals of tylosin and tilmicosin in an animal edibility tissue at the same time.

The invention relates to a tilmicosin micro-capsule preparation, and in particular relates to a tilmicosin micro-capsule preparation and a preparation method of the tilmicosin micro-capsule preparation, belonging to the technical field of veterinary medicine. The tilmicosin micro-capsule preparation comprises an inner core layer and a coating layer, wherein the inner core layer comprises a tilmicosin raw material and macromolecule auxiliary materials, the macromolecule auxiliary materials are selected from one or more than one of 12-carbon fatty acid-18-carbon fatty acid, paraffins and vegetable wax; and the coating layer comprises an inner coating layer and an outer coating layer, wherein the material of the inner coating layer is one or more than one of starch, calcium carbonate and calcium hydrophosphate, and the material of the outer coating layer is acrylic resin. The tilmicosin micro-capsule preparation disclosed by the invention is tasteless, enteric, and good in palatability. According to the invention, the tilmicosin is packed by the macromolecule auxiliary materials, a layer of enteric coating layer is sprayed on the surfaces of the tilmicosin grains in the process of rolling circle when the materials are prepared, and the strong bitter taste and odor of the tilmicosin can be completely covered due to the double-layer package, and the preparation method is simple in technology, and low in cost.

The invention discloses a compound Tilmicosin nanoemulsion antibacterial medicament with a particle size of 1-100 nm, which comprises, by mass, 0.01%-15.2% of Tilmicosin, 0.001%-2.12% of Florfenicol, 13.38%-36% of surfactant, 0%-26.5% of cosurfactant, 2.43%-5.32% of oil, 0.004%-2.12% of Florfenicol solubilizer, 0%-2.07% of Tilmicosin solubilizer and 14.89%-84.17% of distilled water. The sum of the mass percentages of the above components is 100%. The medicament is primrose, clear and transparent liquid in appearance and is characterized by low viscidity, good stability, high dispersibility, quick absorption and the like. The medicament has the advantages of higher bioavailability, longer half-life in a body, lower toxicity and sustained releasing and targeting effect.

The invention provides a process for preparing tilmicosin pellets. The process comprises the following steps: a, uniformly mixing tilmicosin with a diluting agent and a disintegrating agent, adding ethanol, wetting, screening, rounding the particles in a rounding machine, and drying to obtain matrix type sustained-release pellets I; b, dissolving adhesive and carbomer in a 80% ethanol solution, adding tilmicosin into the ethanol solution to constantly stir to form a uniform suspension, adding the pellets I which are prepared in the step a and serve as pill cores into a fluidized bed turntable, spraying the suspension on the surfaces of the pill cores, drying, and collecting the dried pellets II; c, dissolving a coating agent in 80% ethanol, coating the pellets II, and drying to obtain the tilmicosin pellets. The tilmicosin pellets are stable and convenient to use, the bitter taste can be covered, and the pellets can be pressed into pellet tables for pets. The process is suitable for industrial production and popularization application.

The invention relates to a tilmicosin enteric micro pellet. The tilmicosin enteric micro pellet is composed of tilmicosin, a high molecular carrier, a binder, and a coating liquid. Problems of tilmicosin, such as poor palatability and instability under acidic conditions, are solved, and clinical using amount is increased.

The invention relates to a preparation method of tilmicosin liposomes. In the technical scheme, every 3g of tilmicosin raw powder is processed into tilmicosin liposomes by the following steps: (1) preparing a PBS buffer solution with the pH value of 6.5 to 7.5; (2) mixing egg yolk lecithin, cholesterol, octadecylamine, polysorbate-80 and ether in the proportion into a solution; (3) mixing the tilmicosin raw powder with the PBS buffer solution obtained in the step (1), and then pouring the mixture into the solution prepared in the step (2) and uniformly stirring; pulverizing the mixture by ultrasound into a suspension which does not delaminate within at least 5min; (4) transferring the suspension in the step (3) into a rotary evaporator to perform pressure-reduction rotary evaporation so that the suspension is condensed on the wall of the rotary evaporator to form lipid membranes; and (5) washing off the lipid membranes completely with the PBS solution obtained in the step (1), and thencontinuing the pressure-reduction evaporation until the ether is drained entirely to obtain tilmicosin liposome crude products. The method has the advantages of simple steps and strong operability. The prepared tilmicosin liposomes can be easily absorbed after being injected into livestock and poultry organisms; and the phenomenon of local swelling can not be caused.

The invention relates to methods of treating a bacterial infection in a horse or a pig. The method involves administering to the horse or pig a composition comprising (i) a salt made from tilmicosin and a lipophilic acid and (ii) a pharmaceutically acceptable solvent combined together to form an injectable composition that precipitates when injected into water

The invention relates to the technical field of veterinary medicines, and discloses a tilmicosin controlled-release microcapsule preparation containing plant essential oil and a preparation method thereof. The tilmicosin controlled-release microcapsule preparation containing the plant essential oil is prepared from raw materials with the mass percentage of 10% to 50% and the balance of an auxiliary material by adopting mist spraying condensation granulation, wherein the raw materials comprise tilmicosin and the plant essential oil; and the auxiliary material is the mixture of one or more of fatty powder, hydrogenated vegetable oil, stearic acid, stearyl alcohol, glycerin monostearate, monoglyceride and wax. The tilmicosin and the plant essential oil are simultaneously contained in the tilmicosin controlled-release microcapsule preparation containing the plant essential oil, the animal diseases are prevented and controlled, the using amount of antibiotics is reduced, and the pollution caused by the antibiotics is reduced; the bitter taste of the tilmicosin is covered up, the ingestion of animals is induced, and the preparation can be dissolved until reaching intestinal tracts, so that the holding time of effective blood concentration of medicine is prolonged, and the cross contamination caused in the feed mixing process is eliminated.

The invention relates to a tilmicosin soluble powder. The tilmicosin soluble powder is characterized by comprising the following ingredients in percentage by mass: 5-25% of tilmicosin, 3-15% of a cosolvent, 1-3% of a solubilizer, 3-8% of PEG and filler. The invention further provides a preparation method of the tilmicosin soluble powder. According to the tilmicosin soluble powder and the preparation method thereof disclosed by the invention, the preparation process is simple, only simple mixing is needed, the raw materials are all commercially available, low in price and easily available, and the obtained compound preparation is stable in performance; because of addition of the cosolvent and the solubilizer, the tilmicosin soluble powder is good in dissolving property, quite suitable for applications in clinic aspects, capable of meeting the relevant provisions of pharmacopoeia, suitable for industrialized large-scale production, and quite wide in application prospect. The tilmicosin soluble powder has a high practical value.

The invention relates to a Tilmicosin lipidosome preparation and a preparation method. The Tilmicosin lipidosome preparation consists of the Tilmicosin lipidosome and the acceptable vector of a medicament; wherein, the Tilmicosin lipidosome contains Tilmicosin, phospholipid and cholesterin with the weight ratio of 1 : 2 to100 : 1 to 15; the acceptable vector of the medicament comprises an internal buffer system, alkali used for regulating pH, and a frozen-dried supporting agent; the adding amount of the frozen-dried supporting agent calculated according to the weight ratio of the phospholipid is as follows: 0.2 to 4 portions of the frozen-dried supporting agent is added into one portion of the phospholipid; the adding amount of the internal buffer system is 5 to 15mL. The invention has the advantages that: the Tilmicosin content in the unit volume of the Tilmicosin lipidosome preparation is high; the envelop rate is high; the stability is good; moreover, the medicament-loading rate is stable. The medicament in the lipidosome is continuously released, thus remarkably improving the concentration of blood medicament and prolonging the circulating time of the medicament in the blood. The Tilmicosin lipidosome preparation improves the curative effect of the medicament and enhances the clinic usability of the medicament.

The invention belongs to the technical field of veterinary drugs, and particularly relates to a tilmicosin liposome injection and a preparation method thereof. The particle diameter of the tilmicosin liposome injection is 7-10mu m, and every 100ml of injection contains the following components: 5-10g of tilmicosin, 3-5g of soya bean lecithin, 1.5-2.5g of cholesterol, 2g of non-ionic surfactant, 20ml of solvent and the balance of water for injection. The tilmicosin liposome injection provided by the invention greatly reduces the toxic and side effects of the tilmicosin, and can improve the body immunity in use.

The invention discloses a natural compound feed additive for removing veterinary drug residues. The natural compound feed additive is prepared from the following components in parts by weight: 1 part of procyanidine, 1 part of astaxanthin, 1 part of resveratrol, 1 part of curcumin, 1 part of allicin, 1 part of porphyra polysaccharide, 1 part of porphyra polyphenol, 1 part of phycobiliprotein, 1 part of tea polyphenol, 1 part of quercetin, 1 part of chitosan and 1 part of tangeretin; and the ratio of the feed additive to the feed is (1:100) to (1:500) in use. According to the method, the residues of tilmicosin, florfenicol, ceftiofur sodium, thiabendazole, enrofloxacin, gentamicin sulfate, oxytetracycline, sulfadimethoxine and halofuginone hydrobromide in livestock or poultry bodies can be effectively reduced; the natural compound feed additive has the characteristics of being free of pollution and free of public hazard, and can be applied to removal of veterinary drug residues from food animals of which the veterinary drug residues exceed the standard due the factors such as veterinary drug application and environmental pollution, so as to ensure the hygiene and safety of animal food.

The invention relates to a tilmicosin stabilizing preparation. The preparation is neutral and comprises the following components in each 100 ml: 20-50 g of tilmicosin, 30-50 g of penetration cosolvent, 0.2-0.4 g of antioxidant and 0.2 g of chelating agent. According to the invention, the tilmicosin, the penetration cosolvent, the antioxidant and the chelating agent are integrated together to form a faint yellow homogeneous solution, and the pH (Potential of Hydrogen) is 7; when the tilmicosin stabilizing preparation is stored, the character is stable; when the tilmicosin stabilizing preparation is used, an animal organism does not have adverse reactions; the time of reaching a blood concentration peak is much shorter than that of a traditional injection solution, and a tissue seepage force is 4-5 times as much as that of the traditional injection solution, so that the tilmicosin stabilizing preparation is one stable preparation with good curative effects.

The invention belongs to the veterinary antibiotics preparation field and relates to a novel preparation of tilmicosin and salt of same for livestock and a preparation method thereof. The preparation is of lung targeting gelatin microsphere preparation by using tilmicosin or tilmicosin salt as principal components. Clinical drug experiments show that compared with conventional preparations the lung targeting gelatin microsphere of tilmicosin and tilmicosin salt of the invention has better organization selectivity, the drug concentration of lung tissue is higher, the duration is longer, the drug effect is longer and more effective and the side effect is low.

The invention relates to a premix of a veterinary drug for livestock and a preparation method of the premix, and particularly relates to a soluble tilmicosin premix and a preparation method thereof, belonging to the field of veterinary drug processing, and aiming at overcoming the technical defects of low feeding rate of tilmicosin series of products and low utilization rate of tilmicosin in the feed in the prior art. The bad smell and the irritation of tilmicosin are covered in the premix, so that the stability of the drug is greatly improved, and the irritation to the stomach is reduced, the dissolution concentration of tilmicosin is improved, and the bioavailability of organism is greatly increased.

The invention belongs to the technical field of medicinal preparations and relates to a tilmicosin micelle preparation and a preparation method thereof. The tilmicosin micelle preparation comprises the following components in part by weight: 3 to 5 parts of tilmicosin, 5.0 to 15.5 parts of pharmaceutically acceptable carrier materials, 52 to 68 parts of poly(butylene succinate) (PBS ), 0 to 8 parts of additive and a pH modifier, wherein the pH value of the pH modifier is 5 to 7. In the tilmicosin micelle preparation, poloxamer 188 serves as the main micelle component. The poloxamer 188 is an asymmetric amphiphilic block copolymer and can automatically form the micelle in aqueous solution, wherein the hydrophobic block of the micelle gathers inwards and the hydrophilic block gathers outwards. Because the formed micelle is relatively smaller low in particle size, the micelle is higher in retention capability to an inflammatory part and stable onto heat and is not easy to oxidize. The entrapment rate and the drug loading capacity of the tilmicosin micelle preparation are high.